While much attention has focused on ADC and bispecific antibody pipelines with strong out-licensing potential, non-oncology pipelines have received less scrutiny. As the oncology field becomes increasingly crowded, the proportion of domestic non-oncology innovation projects has risen significantly, necessitating an expansion of expertise into non-oncology pipelines. Recently, a family member joined Shanghai-based BAO PHARMA-B (02659), prompting a review of the company's profile. Here are key findings that may serve as useful reference material.
China's innovative drug sector reached a milestone in 2025. Data from the National Medical Products Administration shows 157 out-licensing deals were completed that year, with upfront payments totaling $7 billion and aggregate deal value reaching $135.66 billion—significantly exceeding 2024's 94 deals worth $51.9 billion. According to Pharmaceutical Intelligence, China accounted for 49% of global innovative drug licensing value in 2025, surpassing the United States as the world's top source of innovative drugs for the first time. In Q1 2026, Chinese biopharma out-licensing deals again exceeded $60 billion. The era of "high-quality drugs selling cheaply" has ended.
Goldman Sachs data indicates that Chinese companies now contribute 48% of global R&D pipelines, consolidating their leading position. The innovative drug sector is undergoing a fundamental revaluation. As of April 2, the Hang Seng Hong Kong Innovative Medicine Index rose 56.8% in 2025 and 7.13% in 2026. Many Hong Kong-listed innovative drug stocks have doubled over the past two years.
Recent policies have prioritized self-sufficiency in critical biologics. BAO PHARMA-B's focus aligns with national strategies including the 14th Five-Year Plan for Bioeconomy Development and the Bio-Manufacturing Industry High-Quality Development Action Plan (2023-2027), which emphasize breaking through technological bottlenecks. Shanghai's Three-Year Action Plan for Advanced Manufacturing (2026-2028) further identifies synthetic biology as a key pioneering industry. From a top-down perspective, BAO PHARMA-B operates in a sustainable growth industry aligned with Shanghai's strategic positioning for biopharma development.
The company's pipeline includes 12 candidates, with 3 core programs and 9 others in clinical/preclinical stages.
KJ017 addresses delivery challenges for large-molecule drugs like antibodies, which typically require intravenous infusion due to high molecular weight and viscosity. IV administration necessitates hospital visits and carries risks of infusion reactions. Subcutaneous injection reduces administration time to under 10 minutes with milder adverse events. Recombinant human hyaluronidase enhances subcutaneous permeability by breaking down hyaluronic acid in tissues. Only two such products are approved globally: Halozyme's rHuPH20 and Alteogen's Tergase. Halozyme's partners generate approximately $80 billion annually from subcutaneous antibody therapies. In January, Alteogen licensed ALT-B4 to Tesaro/GSK for $285 million, followed by a Biogen deal in March worth $20 million upfront plus up to $549 million in milestones. Notably, rHuPH20 licenses include target exclusivity, creating supply chain risks for Chinese companies. BAO PHARMA-B's KJ017 holds strategic importance as China's most advanced domestic recombinant hyaluronidase, having received NDA approval with expected H1 launch. Competitor I-Mab's candidate remains in Phase I trials.
Biochemical drugs extracted from animal organs or human urine face quality consistency and contamination risks. Recombinant production via genetic engineering ensures safer alternatives. BAO PHARMA-B's recombinant hyaluronidase represents a leap forward in enabling subcutaneous administration without allergenic risks. The company is advancing KJ017 commercialization through partnerships with WuXi Biologics, QuanSheng Biotech, Shanghai RAAS, and others, plus business development plans with over ten potential collaborators. IND applications to the EMA and FDA are planned. Frost & Sullivan projects China's recombinant hyaluronidase market will grow from RMB417 million in 2025 to RMB4 billion in 2030, a 57.2% CAGR. BAO PHARMA-B is positioned to capture major market share as China's first mover.
KJ103 is the only low-immunogenicity IgG-degrading enzyme in registered clinical trials globally. It holds breakthrough therapy designations for desensitization before kidney transplantation and anti-GBM disease. China performed 15,387 kidney transplants in 2024 (+2.8% YoY), with highly sensitized patients comprising ~10% of recipients. Approximately 150,000 patients await kidney transplants. KJ103's pre-transplant indication completed Phase III trials in March, with anti-GBM Phase III trials expected in H1 2026. Phase II data showed 100% survival at 3 months, with 66.7% of patients maintaining renal function without dialysis. At 6 months, survival remained 100% with 75% dialysis-free. Standard therapy yields 81.2% survival at 3 months and only 30.6% dialysis-free renal function. KJ103 demonstrates best-in-class potential. While targeting rare diseases, supportive policies including 70-day review timelines and market exclusivity make such indications commercially viable for emerging innovators like BAO PHARMA-B.
SJ02, a long-acting recombinant human FSH carboxyl-terminal peptide fusion protein for assisted reproduction, addresses China's growing infertility market. Penetration reached 10.5% in 2025, with infertile couples increasing from 54.8 million pairs in 2020 to an estimated 74.4 million by 2035. The current ovulation induction market (~RMB4.6 billion) is dominated by short-acting products. SJ02 fills the domestic gap for long-acting FSH preparations. An exclusive distribution agreement with Anke Biotech covers Greater China, with initial orders delivered in November. Hospital inclusion procedures are underway, potentially generating tens of millions in incremental revenue this year.
BAO PHARMA-B's synthetic biology platform enables production of difficult-to-express recombinant drugs. KJ101 (recombinant human chymotrypsin), produced via engineered yeast with chaperone proteins, offers higher purity and efficiency while eliminating animal-derived contaminants. It has shown efficacy in burns, wounds, surgical incisions, and diabetic foot ulcers. Phase II enrollment is complete. The domestic chymotrypsin market exceeds RMB2 billion, presenting significant capture potential.
BJ044 (recombinant ulinastatin) addresses pancreatitis, postoperative inflammation, and other conditions. With aging populations and rising immune-related diseases, the ulinastatin market continues high-single-digit growth. Recombinant production significantly reduces costs while maintaining functional integrity. Both KJ101 and BJ044 represent first-in-class recombinant replacements for biochemical extracts with blockbuster potential.
BAO PHARMA-B has established a multi-platform, multi-indication commercialization strategy combining domestic and international expansion, demonstrating strong risk resilience.
The company's revenue grew from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization. KJ017's expected H1 approval coincides with strong subcutaneous injection trends—76% of FDA-approved high-concentration antibodies in 2024 were subcutaneous formulations, with >90% patient preference. Expanded partnerships for KJ017's hydration assistance indication should accelerate BAO PHARMA-B's path to breakeven.
Despite multiple clinical programs, R&D spending remains manageable. 2025 R&D investment reached RMB248 million, slightly below 2024 levels due to reduced share-based compensation. Clinical trial costs actually increased by over RMB28 million. The company's 2025 net loss of RMB395 million (up RMB31 million YoY) reflected non-operating factors including litigation provisions of RMB56.76 million and net foreign exchange losses of RMB7.5 million. Excluding these one-time items, adjusted profitability trends positively. Cash and equivalents stood at RMB1.2416 billion against debt of RMB312.4 million (RMB114 million due within one year), indicating no solvency concerns.
With market capitalization exceeding RMB30 billion and inclusion in Stock Connect, potential A-share listing could further strengthen liquidity. The company's focus on resolving biotech supply chain constraints, combined with improving innovative drug sentiment, warrants ongoing attention.
Comments